PUBLISHED ASSESSMENT

Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2025–26 Influenza Season | MMWR

This compact public record contains an assessment and source links. It does not contain article text, reader identity, browsing history, or private notes.

Historical provenance limit: this assessment has a recorded retrieval URL from before Beaconwright’s current publisher-verification boundary. It has not been reverified under the current boundary.

Open original article

Most clinical and regulatory claims are well sourced, and the report offers unusually clear authorship, methods, tables, disclosures, and references. Its principal weakness is the nationwide thimerosal restriction: the report acknowledges that usual evidence-review procedures were not used and supplies no benefit–risk rationale, despite accessible safety and access context. This materially lowers balance and evidence support while the explicit disclosure preserves substantial transparency.

Evidence support

Substantial (72/100)

FDA records support the stated 2025–26 vaccine composition and the FluMist and Flublok labeling changes.
The routine vaccination, timing, allergy, and special-population guidance is linked to prior evidence reviews and numerous studies.
The thimerosal restriction is a material exception: the report acknowledges that no GRADE or Evidence-to-Recommendations assessment was performed and that the Influenza Work Group did not review it.
CDC and FDA evidence summaries report no demonstrated harm from vaccine-level thimerosal beyond rare hypersensitivity reactions, leaving the restriction without a clearly presented evidentiary basis.

Balance & context

Mixed (57/100)

The report carefully describes contraindications, precautions, waning immunity, exceptions, and uncertainty in the egg-allergy evidence.
It transparently identifies off-label recommendations and distinguishes FDA labeling from ACIP guidance.
It does not proportionately discuss the established thimerosal safety evidence, multidose-vial contamination prevention, access implications, or committee dissent surrounding the new restriction.
Readers receive no explicit benefit–risk rationale for a recommendation affecting nearly all influenza-vaccine recipients.

Transparency

Substantial (77/100)

Authors, affiliations, publication date, correspondence, conflicts, off-label uses, methods, meeting dates, tables, and extensive references are disclosed.
Regulatory records, evidence frameworks, package inserts, meeting materials, and studies are directly identifiable.
The report explicitly discloses that the thimerosal recommendation bypassed the usual work-group, GRADE, and EtR processes.
Transparency is limited because the evidence-selection method, rationale, and benefit–risk analysis for that recommendation are not supplied.

Confidence and coverage

Confidence in this analysis: High confidence

Evidence coverage: Substantial coverage

Key recommendations and regulatory changes were checked against accessible CDC and FDA records.
The assessment did not independently verify every cited study, package insert detail, or table entry.

The full article text and extensive references were available.
Core updates were corroborated through direct FDA and CDC records.
The principal evidentiary limitation is expressly acknowledged by the report itself.

Sources considered

Influenza Vaccine Composition for the 2025–2026 U.S. Influenza Season — Confirms the recommended trivalent strains and surveillance-based selection process.
FDA Approves Nasal Spray Influenza Vaccine for Self- or Caregiver-Administration — Confirms the September 20, 2024 FluMist approval and eligible age groups.
March 31, 2025 Approval Letter — Flublok — Confirms expansion of Flublok’s indication to persons aged 9–17 years.
Meeting of the Advisory Committee on Immunization Practices — June 25–26, 2025 — Documents the votes and competing views concerning thimerosal restrictions and vaccine access.
Thimerosal-Containing Vaccines and Neurodevelopmental Outcomes: Review of the Evidence — Reports no evidence of harm from vaccine-preservative use beyond local hypersensitivity reactions.
Thimerosal and Vaccines — Summarizes safety evidence and explains the contamination-prevention and supply roles of preservatives in multidose vials.

This assesses evidence and presentation; it is not an overall truth verdict.

Reassess

⚠ Paid reassessment incurs a charge. Opening this page does not start a run or incur a charge.

To request a new assessment, sign in to My library, watch this record, and select Request new assessment. Requests await separate approval and do not themselves start a paid run.

A new assessment may differ. Earlier published results remain in history.

Open My library

Assessment history

Published assessment trend

Available public snapshots only; this is not a count of all executions. Corrections may include earlier scores. Gaps mean not scored or not recorded. Different scores do not establish changed source evidence.

Evidence support — solid blueBalance & context — dashed purpleTransparency — dotted green

Reassess ⚠

Recorded public scores (0–100)
Date	Evidence support	Balance & context	Transparency
2026-09-12 (current)	72	57	77